Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0189)
Name
Dyclonine
Synonyms
dyclonine; Dyclocaine; 586-60-7; Dyclonin; Dyclocainum; Diclonina; Dycloninum; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; Dycloninum [INN-Latin]; Diclonina [INN-Spanish]; 4'-Butoxy-3-piperidinopropiophenone; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 3-Piperidino-4'-butoxypropiophenone; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-; Dyclonine (INN); Diclonia; 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 4-butoxy-beta-piperidinopropiophenone; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 4-n-butoxy-beta-(1-piperidyl)propiophenone; CHEBI:4724; PROPIOPHENONE, 4'-BUTOXY-3-PIPERIDINO-; 078A24Q30O; DYCLONINE [INN]; Dyclonine [INN:BAN]; NCGC00016498-01; CAS-536-43-6; BRN 0224037; UNII-078A24Q30O; Dyclone (Salt/Mix); Tanaclone (Salt/Mix); Spectrum_001016; DYCLONINE [MI]; Prestwick0_000264; Prestwick1_000264; Prestwick2_000264; Prestwick3_000264; Spectrum2_001013; Spectrum3_000410; Spectrum4_000529; Spectrum5_000951; DYCLONINE [VANDF]; DYCLONINE [WHO-DD]; SCHEMBL25773; BSPBio_000108; BSPBio_001940; KBioGR_001137; KBioSS_001496; DivK1c_000632; 1-propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl); SPBio_001165; SPBio_002327; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; BPBio1_000120; GTPL7173; CHEMBL1201217; DTXSID6047864; KBio1_000632; KBio2_001496; KBio2_004064; KBio2_006632; KBio3_001160; BZEWSEKUUPWQDQ-UHFFFAOYSA-N; NINDS_000632; EX-A5489; AM9638; STK524544; AKOS000505031; DB00645; IDI1_000632; NCGC00016498-02; NCGC00016498-03; NCGC00016498-04; NCGC00016498-05; AC-12286; SBI-0051358.P003; AB00053467; FT-0660914; C07881; D07881; AB00053467_13; AB00053467_14; EN300-25300221; Q425386; BRD-K72259270-003-05-8; BRD-K72259270-003-15-7; N8R

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C18H27NO2
IUPAC Name
1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one
Canonical SMILES
CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2
InChI
InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
InChIKey
BZEWSEKUUPWQDQ-UHFFFAOYSA-N
PubChem CID
3180
TTD Drug ID
D04QLR
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Head neck squamous cell carcinoma ICD-11: 2D60
 Disease Info 
Responsed Regulator Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) Suppressor
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model OSC-19 cells Tongue squamous cell carcinoma Homo sapiens CVCL_3086
HSC-2 cells Oral cavity squamous cell carcinoma Homo sapiens CVCL_1287
HSC-3 cells Oral squamous cell carcinoma Homo sapiens CVCL_1288
HSC-4 cells Cervical lymph node Homo sapiens CVCL_1289
SCC-25 cells Squamous carcinoma Homo sapiens CVCL_1682
DMS114 cells Lung small cell carcinoma Homo sapiens CVCL_1174
HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
4T1 cells Mammary carcinoma Mus musculus CVCL_0125
In Vivo Model
HSC-2 or K19-Wnt1/C2mE-KP cells (2 x 106 cells per site) were implanted subcutaneously in the flank of athymic nude mice (CLEA Japan) or C57BL6 mice (CLEA Japan), respectively. The mice were then injected intraperitoneally with physiological saline or sulfasalazine (350 mg/kg per day), or with combinations of physiological saline, sulfasalazine (400 mg/kg per day), and dyclonine hydrochloride (5 mg/kg per day).

    Click to Show/Hide
Response regulation Sulfasalazine-resistant head and neck squamous cell carcinoma (HNSCC) cells were found to highly express ALDH3A1 and knockdown of ALDH3A1 rendered these cells sensitive to sulfasalazine. The combination of dyclonine and sulfasalazine cooperatively suppressed the growth of highly ALDH3A1-expressing HNSCC or gastric tumors that were resistant to sulfasalazine monotherapy.
References
Ref 1 Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. Oncotarget. 2018 Sep 18;9(73):33832-33843. doi: 10.18632/oncotarget.26112. eCollection 2018 Sep 18.